Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group

Laurie H. Sehn, David MacDonald, Sheldon Rubin, Guy Cantin, Morel Rubinger, Bernard Lemieux, Sanraj Basi, Kevin Imrie, Randy D. Gascoyne, Jonathan Sussman, Bingshu E. Chen, Marina Djurfeldt, Lois Shepherd, Stephen Couban, Michael Crump